A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib

PLoS Computational Biology

Volumn 6, Issue 11, 2010, Pages

  Burkard, Thomas R ^a   Rix, Uwe ^a   Breitwieser, Florian P ^a   Superti Furga, Giulio ^a   Colinge, Jacques ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DRUG INTERACTIONS; DRUG THERAPY; MOLECULAR BIOLOGY; PROTEINS;

BIOMEDICAL RESEARCH; CELL-BE; CELL/B.E; CELL/BE; COMPUTATIONAL APPROACH; DRUG ACTION; HUMAN CELLS; KINASE INHIBITORS; MECHANISM OF ACTION; NEW APPLICATIONS;

DISEASES;

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; BAFETINIB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; MATHEMATICAL COMPUTING; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; METHODOLOGY; PROTEIN ANALYSIS; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEOMICS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 78649683041     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1001001     Document Type: Article

References (54)

1. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology. Bioinformatics 25: 2466-2472.
2. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063.
3. Fernbach NV, Planyavsky M, Muller A, Breitwieser FP, Colinge J, et al. (2009) Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. J Proteome Res 8: 4753-4765.
4. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-620.
5. Rix U, Superti-Furga G (2009) Target profiling of small molecules by chemical proteomics. Nat Chem Biol 5: 616-624.
6. Zhu M, Gao L, Li X, Liu Z, Xu C, et al. (2009) The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network. J Drug Target 17: 524-532.
7. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 25: 309-316.
8. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
9. Jonsson PF, Bates PA (2006) Global topological features of cancer proteins in the human interactome. Bioinformatics 22: 2291-2297.
10. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263-266.
11. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R (2007) Network analysis of FDA approved drugs and their targets. Mt Sinai J Med 74: 27-32.
12. Wachi S, Yoneda K, Wu R (2005) Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21: 4205-4208.
13. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
14. Wu X, Jiang R, Zhang MQ, Li S (2008) Network-based global inference of human disease genes. Mol Syst Biol 4: 189.
15. Dartnell L, Simeonidis E, Hubank M, Tsoka S, Bogle ID, et al. (2005) Robustness of the p53 network and biological hackers. FEBS Lett 579: 3037-3042.
16. Li F, Li P, Xu W, Peng Y, Bo X, et al. PerturbationAnalyzer: a tool for investigating the effects of concentration perturbation on protein interaction networks. Bioinformatics 26: 275-277.
17. Maslov S, Ispolatov I (2007) Propagation of large concentration changes in reversible protein-binding networks. Proc Natl Acad Sci U S A 104: 13655-13660.
18. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
19. Barrenas F, Chavali S, Holme P, Mobini R, Benson M (2009) Network properties of complex human disease genes identified through genome-wide association studies. PLoS One 4: e8090. doi:10.1371/journal.pone.0008090.
20. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, et al. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106: 3948-3954.
21. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044.
22. Ong SE, Schenone M, Margolin AA, Li X, Do K, et al. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A 106: 4617-4622.
23. Sharma K, Weber C, Bairlein M, Greff Z, Keri G, et al. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat Methods 6: 741-744.
24. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, et al. (2006) BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34: D535-539.
25. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, et al. (2004) The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 32: D449-451.
26. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-772.
27. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, et al. (2010) The IntAct molecular interaction database in 2010. Nucleic Acids Res 38: D525-531.
28. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, et al. (2010) MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38: D532-539.
29. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, et al. (2009) Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A 106: 7414-7419.
30. UniProt-Consortium (2010) The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res 38: D142-148.
31. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
32. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2010) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 38: D5-16.
33. Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, et al. (2010) A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO- 406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 24: 44-50.
34. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, et al. (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272.
35. Carey VJ, Gentry J, Whalen E, Gentleman R (2005) Network structures and algorithms in Bioconductor. Bioinformatics 21: 135-136.
36. R-Development-Core-Team (2010) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, Available: http://www.R-project.org. ISBN 3-900051-07-0.
37. Carey V, Long L, Gentleman RRBGL (2010) An interface to the BOOST graph library. Available: http://bioconductor.org/packages/release/bioc/html/RBGL.html. Accessed 13 September 2010.
38. Carlson M, Falcon S, Pages H, Li NGO. db: A set of annotation maps describing the entire Gene Ontology. Available: http://bioconductor.org/packages/release/data/annotation/html/GO.db.html. Accessed 13 September 2010.
39. Gentleman R, Whalen E, Huber W, Falcon S graph: A package to handle graph data structures. Available: http://bioconductor.org/packages/release/bioc/html/graph.html. Accessed 13 September 2010.
40. Tierney L, Rossini AJ, Li N, Sevcikova H snow: Simple Network of Workstations. Available: http://cran.r-project.org/web/packages/snow/index.html. Accessed 13 September 2010.
41. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
42. Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, et al. (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8: 129-140.
43. Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210.
44. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, et al. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187.
45. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279: 34227-34239.
46. Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, et al. (2009) Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 50: 2017-2029.
47. Li J, Rix U, Fang B, Bai Y, Edwards A, et al. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6: 291-299.
48. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, et al. (2007) Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 96: 808-814.
49. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
50. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T (2008) Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCRABL gene amplification. Int J Cancer 122: 2621-2627.
51. Kantarjian H, Coutre PL, Cortes J, Pinilla-Ibarz J, Nagler A, et al. (2010) Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116: 2665-2672.
52. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, et al. (2010) Inhibition of IGFIR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med 14: 1777-92.
53. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019.
54. Wolf A, Couttet P, Dong M, Grenet O, Heron M, et al. (2010) Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 34: 1180-1188.